Major depressive disorder (MDD) is a pervasive and debilitating illness, with a recurrent course and chronic prognosis. Although effective treatments for MDD exist, there is a pressing need to characterize relapse vulnerability in order to design effective prophylactic care. To date, heterogeneity within depression neuroimaging research has made it difficult to establish a reliable biomarker of disorder susceptibility. In this paper, we review neuroimaging evidence for the assessment of MDD vulnerability, theorizing that current findings can be broadly distinguished between those indicating the presence of depressive episodes and those indicating MDD vulnerability during symptom remission. We argue that unlike the amygdala hyperactivity and prefrontal hypoactivity observed during MDD episodes, prefrontal hyperactivity may be a characteristic of dysphoric cognition during symptom remission that indicates MDD vulnerability and relapse risk. Drawing on current research of normative emotion regulation, we describe a potential test of MDD vulnerability, employing emotional challenge paradigms that induce cognitive reactivity -the increased endorsement of negative self-descriptions during a transient dysphoric mood. Relative to a normative model of prefrontal function, the neuroimaging assessment of cognitive reactivity may provide a reliable indicator of MDD vulnerability, advancing the field of biomarker research as well as the delivery of preventative treatment on an individual basis.
introduction
Major depressive disorder (MDD) is a common and debilitating disorder, with prevalence rates between 3-13% [1, 2] and lifetime risk estimated at 17-19% [3, 4] . MDD carries enormous social costs due to its high risk for relapse and recurrence [1, [5] [6] [7] , and is one of the leading causes of disability worldwide [8] , significantly increasing social impairment and mortality [9] [10] [11] . Despite the clinical adoption of efficacious treatments [12, 13] , MDD may be rising in prevalence [14] , and remains a disorder of global health concern.
There are likely multiple determinants of MDD susceptibility, including genetic [15] , physiological [16] , psychological [17] [18] [19] [20] [21] , and socio-economic [22, 23] factors. While heritability studies suggest that while MDD has a strong genetic component [24] , the majority of risk still comes from environmental factors, accounting for 60-70% of the variance in familial inheritance. This environmental contribution suggests that psychosocial interventions may powerfully combat or even prevent MDD [25] . Neuroimaging allows us to explore the brain mechanisms underlying psychopathology and its resolution [26] [27] [28] . In this paper, we review neuroimaging evidence for the assessment of MDD vulnerability, demonstrating how translation of the normative features of cognitive control in the brain can be applied to investigate MDD vulnerability. We argue that a person's neural response to negative mood provocation can predict depression risk, and may substantially advance our understanding of MDD pathophysiology, the heterogeneity of clinical presentations and treatment responsiveness. Uncovering mechanisms supporting the onset of depressive symptoms would enable the targeting of preventative interventions towards individuals at increased risk for MDD [29, 30] .
mdd vulnerability and the brain
The same neural networks associated with normal emotional expression appear to be involved in affective disorders [31] . Specifically altered anatomy and neurophysiological activity has been observed throughout the prefrontal cortex (PFC), including its medial (MPFC), dorsolateral (DLPFC) and ventromedial (VMPFC) aspects, as well as in subcortical structures such as the amygdala and hippocampus [32] . Despite variability in neuroimaging research findings, considerable progress has been made in identifying some common functional features of MDD in the brain.
It should be made clear from the outset that the study of a biomarker of MDD susceptibility must focus on the contributing factors to episode onset rather than the detection of episode states themselves. Thus, while the traditional profile for depression in the brain is one of PFC hypoactivity and amygdala hyperactivity [33, 34] , the pathophysiology leading to this depressed state may be markedly different, associated with a different biomarker profile.
The amygdala and emotional salience
Most descriptions of affective dysfunction begin with the amygdala. Traditionally characterized as a threat detector [35, 36] , this subcortical region displays greater activity in MDD and related disorders [37] [38] [39] [40] . However, several studies have now demonstrated greater amygdala responsiveness to emotional arousal in general than negative valence in particular [41, 42] . As such, rather than dysphoric affect, the amygdala has increasingly been associated with emotional salience [43] , whether positive or negative [44] [45] [46] . Indeed, amygdala reactivity may be shaped by a host of factors, including short-term goals and motivational context [47, 48] , chronic personality traits such as neuroticism [49] , or stimulus properties such as novelty [50, 51] . Thus while amygdala reactivity may be an important component of depressive information processing, we must begin to more broadly consider amygdala reactivity to emotionally-relevant stimuli, including positive and goal-relevant stimuli, to assess its precise information processing role in MDD.
Even given a bias in amygdala responsiveness to negative stimuli, it appears that the [69] . The inability to disengage from negative self-focus is an emerging theory of MDD that predicts such maladaptive DLPFC recruitment [70] .
Increased PFC activity in MDD may also reflect an inefficiency of cortical processing, as depressed individuals ineffectively attempt to regulate negative emotions [56] . Thus while patients with mood disorders tend to show reduced PFC metabolism [71] , this lower baseline of activity may result in greater patterns of neural reactivity when attempting to regulate negative emotion [38] , particularly in the right DLPFC [72] .
The VMPFC and subgenual cingulate as a subcortial-PFC bridge
The VMPFC and subgenual cingulate are anatomically situated at the nexus between subcortical structures and the PFC. The VMPFC receives connections from both exteroceptive [73] and interoceptive [74] cortices, and has been viewed as a polymodal convergence zone supporting emotional awareness [75] .
Relative to the more lateral orbitofrontal aspects of the ventral forebrain, the VMPFC is particularly involved in self-referential rather than conceptual or objective estimation of emotional significance [76] .
Mounting evidence suggests that MDD may be driven by compromised PFC modulation of subcortical circuitry, particularly in its treatment-resistant and recurrent cases [77, 78] . In these cases the normally observed connectivity between the PFC and amygdala via the VMPFC appears to be disrupted, suggesting However, the electrical disruption of VMPFC activity, particularly in the subgenual cingulate is a promising treatment of seeminglyintractable depression [86, 87] . Whether psychosocial interventions can also act upon this deregulated VMPFC-subcortical network is a question for future research.
The MPFC and self-referential focus
The anatomical and functional intermediary between DLPFC regulatory control and VMPFC affective representation lies in the MPFC. This region is associated with the 'default' mode of the brain, and is often active while individuals are at rest [88] , driving automatic and habitual evaluation, and has been independently associated particularly with explicit selfevaluation [89] . Habitual, negative selfevaluation is highly prevalent in MDD in the form of rumination [68] , and so maladaptive activity in the MPFC is a strong candidate mechanism supporting the chronic dysphoria observed in depression. It should be noted that it is difficult to distinguish between the MPFC and the rostral anterior cingulate as the terms are used interchangeably in the literature, and thus we will consider evidence regarding both areas in this section. 
The hippocampus and overgeneral memory
Depression is linked to subcortical changes that extend beyond the immediate attribution of emotional salience found in the amygdala.
It is well-established that long term MDD is associated both with memory impairment [103, 104] and with reduced hippocampal volume [105] [106] [107] [108] , and that these memory deficits are associated with reduced hippocampal activity [109] . Overgeneral memories are common in MDD, in which patients recall general semantic facts about themselves (e.g., "I always have a bad time at the beach") rather than specific autobiographical episodes (e.g., "this one time I went to the beach and got a sunburn on my knee") [110] [111] [112] . This overgeneralization of memory appears to be driven by ruminative processes [113] , and is a predictor of depression severity [110, 114] . [143, 144] . Reactivity is associated with rumination, and predicts MDD vulnerability above and beyond baseline rumination scores [145] . Critically, cognitive reactivity directly predicts depressive relapse [146] .
The research literature proposes several explanatory mechanisms for cognitive reactivity, and helps to account for other cognitive constructs' contribution to depressive affect. For instance, cognitive reactivity appears to be a mediating variable in explaining why the Big-5 personality trait of Neuroticism predisposes individuals to depression [147] . At the physiological level, tryptophan depletion appears to increase cognitive reactivity patterns and promote negative affect [148] .
The centrality of reactivity for explaining mood challenge at multiple levels of analysis suggests that this phenomenon may be a powerful explanatory step in the translation of psychological and physiological factors to the subjective experience of dysphoria.
Lending credence to the importance of reactivity for determining subjective wellbeing, interventions that focus on cognitive reactivity to emotional provocation have also demonstrated marked success in reducing MDD vulnerability by lowering depressive relapse rates. Both Cognitive Behavioral Therapy [149] and Mindfulness-Based Cognitive Therapy [150] [151] [152] appear to reduce relapse risk by increasing metacognitive awareness, thereby disrupting habitual cognitive reactivity patterns [153] . The concept of decentering experience seems to be a candidate factor driving reduced relapse risk, reducing the obligatory connection between negative emotions and self-referential inference [154] .
While cognitive reactivity may be studied through behavioral testing, it is likely that these exaggerated reactivity responses have pervasive functional biomarkers in the brain that may elucidate depressive pathophysiology.
MDD episodes are characterized by hyperactive VMPFC and hypoactive DLPFC recruitment, and the normalization of these patterns is associated with successful recovery [38, 155, 156] . However, studies of treatment response, focusing on the determinants of disorder vulnerability, paint a different picture:
emotional reactivity to a dysphoric stressor in the form of DLPFC activation is maladaptive and predicts longer depressive episodes [157] .
Another study observed that patients exhibited reduced reactivity to emotional stimuli in the VMPFC and subcortical regions, but increased reactivity in the left temporal pole and right DLPFC. Successful treatment reduced this reactivity and restored subcortical tone [158] .
Rumination, a cognitive predictor of MDD, has been associated with dorsal MPFC activation in healthy individuals [159] and with both DLPFC and VMPFC activation in MDD patients [69] .
This pattern of exaggerated dorsal PFC reactivity
to emotional challenge appears to be a flexible indicator of depression course, and is founded upon behavioral evidence linking neural activity to maladaptive ruminative cognition.
The neural signal of dorsal PFC regions during cognitive reactivity to emotional challenge is thus an exciting candidate biomarker of MDD vulnerability.
The biomarker approach
The Seeking to capitalize on the existing behavioral literature surrounding emotional reactivity and depression risk, we performed a prospective neuroimaging study in which we observed that future relapse into MDD was predicted by neural reactivity to emotional challenge [58] . to distinguish between specific subtypes of depression [25] . In this review we focused on one example of reactivity that may be used as a biomarker, namely PFC reactivity in response to an emotional challenge. Rather than using a data driven approach, the investigation of this biomarker is driven by a theory of affective deregulation in MDD. Recruitment of a VMPFC pathway is traditionally found during the effortful regulation of affect, attempting to form new evaluations of an aversive experience [168, 169] .
discussion
However, what appears to be a normative regulatory process in healthy individuals may manifest as a biomarker of psychopathology in the context of a depressive history. Furthermore, the co-activation of the VMPFC pathway with the DLPFC in depressed patients is unusual, as these regions tend to be negatively correlated in healthy individuals [170] . Thus what is normative at the level of a specific brain structure may be abnormal in the context of broad neuronal activity in a given paradigm.
While the data presented in our study of PFC reactivity is exciting and appears to have 
